WeVote

Bill

Bill

HB 80

Breakthrough Therapies for Veteran Suicide Prevention, Advisory Council on; established, report.

2025 Regular Session Introduced by Mike Jones

Virginia establishes advisory council to study and report on breakthrough therapies for treating veteran suicide, addressing gaps in mental health treatment options.

Left in Rules
0
WeVote Research Nonpartisan
Bill Summary · HB 80

Legislative bill overview

HB 80 establishes an Advisory Council on Breakthrough Therapies for Veteran Suicide Prevention in Virginia. The council would study and report on emerging therapeutic approaches—potentially including psychedelic-assisted therapies and other innovative treatments—to address the high suicide rate among veterans. The bill requires the council to deliver findings and recommendations to the Virginia General Assembly.

Why is this important

Veteran suicide remains a significant public health crisis, with rates substantially higher than the general population. By formally studying breakthrough therapies, Virginia could potentially identify evidence-based treatments to improve mental health outcomes and inform policy decisions about which experimental treatments warrant further investigation or clinical access.

Potential points of contention

  • Federal/state regulatory overlap: Breakthrough therapies like psilocybin or MDMA-assisted therapy remain federally controlled substances, creating tension between state study recommendations and federal law enforcement/drug policy
  • Research scope and credibility: Questions about whether the council has sufficient scientific expertise, funding, and independence to evaluate emerging therapies versus being influenced by advocacy groups or incomplete evidence
  • Implementation feasibility: Unclear whether recommendations would lead to actual treatment access, funding mechanisms, or legislative action, potentially making the council advisory-only without meaningful veteran impact

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.